Open AccessThe efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin β in peritoneal dialysis patients with chronic renal anaemia
Author(s) -
W Grzeszczak,
Władysław Sułowicz,
Piotr Rutkowski,
Amedeo F. De Vecchi,
Renzo Scanziani,
Pierre–Yves Durand,
Auxiliadora Bajo,
Vassilis Vargemezis
Publication year - 2005
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfh761
Subject(s) - medicine , peritoneal dialysis , kidney disease , erythropoietin , hemodialysis , dialysis , epoetin alfa , intensive care medicine , urology , surgery
Reducing the dosage frequency of subcutaneous epoetin in peritoneal dialysis (PD) patients is convenient and should improve patient satisfaction and, possibly, compliance. We investigated if a weekly dosage of epoetin beta in PD patients safely maintained haemoglobin (Hb) concentrations equivalent to those obtained with previous twice- or thrice-weekly administration. In addition, we investigated if a fortnightly dosage of epoetin beta was safe and as effective as previous weekly administration.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom